Swiss National Bank raised its position in InVitae Corp (NYSE:NVTA) by 23.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,200 shares of the medical research company’s stock after purchasing an additional 11,800 shares during the quarter. Swiss National Bank owned 0.12% of InVitae worth $574,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC grew its holdings in shares of InVitae by 190.1% in the 3rd quarter. Perceptive Advisors LLC now owns 1,884,500 shares of the medical research company’s stock valued at $17,657,000 after acquiring an additional 1,235,000 shares in the last quarter. Orbimed Advisors LLC grew its holdings in shares of InVitae by 232.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,518,197 shares of the medical research company’s stock valued at $14,226,000 after acquiring an additional 1,061,531 shares in the last quarter. Ark Investment Management LLC grew its holdings in shares of InVitae by 30.4% in the 2nd quarter. Ark Investment Management LLC now owns 982,170 shares of the medical research company’s stock valued at $9,390,000 after acquiring an additional 229,189 shares in the last quarter. State Street Corp grew its holdings in shares of InVitae by 43.1% in the 2nd quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock valued at $5,528,000 after acquiring an additional 174,016 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of InVitae by 39.0% in the 2nd quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock valued at $4,140,000 after acquiring an additional 121,409 shares in the last quarter. 73.58% of the stock is currently owned by hedge funds and other institutional investors.
InVitae Corp (NVTA) opened at $7.56 on Friday. The company has a quick ratio of 2.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.35. InVitae Corp has a 1-year low of $4.11 and a 1-year high of $10.41.
InVitae (NYSE:NVTA) last issued its quarterly earnings data on Monday, February 12th. The medical research company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.17). The company had revenue of $25.40 million for the quarter, compared to analyst estimates of $24.18 million. InVitae had a negative return on equity of 124.43% and a negative net margin of 180.85%. The company’s revenue was up 175.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.69) earnings per share. equities analysts predict that InVitae Corp will post -2.28 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on InVitae from $13.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, February 13th. Benchmark reduced their price target on InVitae from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, February 13th. ValuEngine cut InVitae from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Leerink Swann reduced their price target on InVitae from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services began coverage on InVitae in a report on Friday, January 5th. They set a “buy” rating and a $15.00 price target for the company. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $11.00.
COPYRIGHT VIOLATION WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/17/swiss-national-bank-purchases-11800-shares-of-invitae-corp-nvta.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.